Committee MemberEmploymentConsultantSpeakers BureauOwnership/Partnership/PrincipalPersonal ResearchInstitutional, Organizational, or Other Financial BenefitExpert Witness
John U. Doherty, ChairJefferson Medical College of Thomas Jefferson University—Professor of MedicineNoneNoneNoneNoneNoneNone
Ty J. GluckmanProvidence Heart and Vascular Institute—Medical DirectorNoneNoneNoneNoneNoneNone
William J. HuckerMassachusetts General Hospital—Fellow in Cardiovascular MedicineNoneNoneNoneNoneNoneNone
James L. Januzzi Jr.Massachusetts General Hospital—Director, Dennis and Marilyn Barry Fellowship in Cardiology Research, Cardiology Division; Harvard Medical School—Hutter Family Professor of MedicineNoneNoneNoneNone
  • Boehringer Ingelheim (DSMB)

  • Janssen Pharmaceuticals, (DSMB)

Thomas L. OrtelDuke University Medical Center—Chief, Division of Hematology; Professor of Medicine and Pathology; Medical Director, Clinical Coagulation LaboratoryNoneNoneNoneNoneNoneNone
Sherry J. SaxonhouseCarolinas HealthCare System Sanger Heart & Vascular Institute—Cardiac Electrophysiology Associate Professor of MedicineNoneNoneNoneNoneNoneNone
Sarah A. SpinlerUniversity of the Sciences Philadelphia College of Pharmacy—Professor of Clinical Pharmacy
  • Boehringer Ingelheim Pharmaceuticals, Inc.

  • Daiichi Sankyo


To avoid actual, potential, or perceived conflicts of interest that may arise as a result of industry relationships or personal interests among the writing committee, all members of the writing committee, as well as peer reviewers of the document, are asked to disclose all current healthcare-related relationships, including those existing 12 months before initiation of the writing effort. The American College of Cardiology (ACC) Task Force on Clinical Expert Consensus Documents reviews these disclosures to determine what companies make products (on market or in development) that pertain to the document under development. Based on this information, a writing committee is formed to include a majority of members with no relevant relationships with industry (RWI), led by a chair with no relevant RWI. RWI is reviewed on all conference calls and updated as changes occur. Author RWI pertinent to this document is disclosed in this table and peer reviewer RWI is disclosed in Appendix 2. Additionally, to ensure complete transparency, authors’ comprehensive disclosure information—including RWI not pertinent to this document—is available online. Disclosure information for the ACC Task Force on Clinical Expert Consensus Documents is also available online, as is the ACC disclosure policy for document development.

This table represents the relationships of committee members with industry and other entities that were determined to be relevant to this document. These relationships were reviewed and updated in conjunction with all meetings and/or conference calls of the writing committee during the document development process. The table does not necessarily reflect RWI at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of ≥5% of the voting stock or share of the business entity, or ownership of ≥$5,000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Please refer to for definitions of disclosure categories or additional information about the ACC/American Heart Association Disclosure Policy for Writing Committees.

DSMB = data and safety monitoring board.

  • Significant relationship.